Switching GLP-1 Medications: A Complete Transition Guide
Considering switching from semaglutide to tirzepatide, or the reverse? Here is everything you need to know about safely transitioning between GLP-1 medications.
Medical Disclaimer: Do not switch medications without consulting your provider. Dosing conversions require medical judgment based on your individual response and health profile.
Switching GLP-1 medications is becoming increasingly common as patients seek better results, fewer side effects, or more affordable options. The good news: transitions are generally smooth when done properly.
When Switching Makes Sense
- Plateau: Weight loss has stalled for 8+ weeks despite dose optimization
- Side effects: Persistent GI issues on one medication may improve on another
- Cost: Brand-name to compounded, or between compounded options
- Availability: Supply issues with one medication
- Greater efficacy desired: Semaglutide to tirzepatide for more weight loss
- New options: Interest in retatrutide as it becomes available
Approximate Dose Equivalents
Semaglutide to Tirzepatide Conversion
| Semaglutide Dose | Suggested Tirzepatide Start |
|---|---|
| 0.25-0.5mg | 2.5mg |
| 1.0mg | 5mg |
| 1.7mg | 7.5mg |
| 2.4mg | 7.5-10mg |
These are approximate guidelines. Your provider will customize based on your response.
The Transition Process
- Last dose of current medication: Take your final dose on your regular injection day
- Wait one week: Skip one week (no injection) to allow the first medication to clear
- First dose of new medication: Begin the new medication on what would have been your next injection day
- Monitor closely: Track side effects, appetite, and weight during the first 4 weeks
- Adjust as needed: Your provider may modify the dose based on your response
What to Expect During the Switch
- Week 1 (washout): Appetite may increase slightly as the first medication clears
- Weeks 2-3: New medication takes effect. Side effects may resemble initial titration
- Weeks 4-8: Stabilization. Your body adjusts to the new medication profile
- Beyond 8 weeks: Clear picture of how the new medication works for you
Frequently Asked Questions
Can I switch from semaglutide to tirzepatide?
Yes, and it is increasingly common. Your provider will determine an appropriate starting dose on tirzepatide based on your current semaglutide dose. Most patients start tirzepatide at 5mg if they were on semaglutide 1mg+. The switch is typically done on the same injection day — your last semaglutide dose is followed by your first tirzepatide dose the next week.
Why would someone switch GLP-1 medications?
Common reasons include: weight loss plateau on current medication, persistent side effects that may be better on an alternative, desire for greater weight loss (tirzepatide typically produces more), cost considerations (semaglutide is $125/mo vs tirzepatide at $125/mo), or interest in trying retatrutide.
Will I lose more weight if I switch from semaglutide to tirzepatide?
Possibly. Clinical trials show tirzepatide produces greater average weight loss than semaglutide. However, individual responses vary. Some patients who plateaued on semaglutide see renewed weight loss on tirzepatide; others see similar results. A switch is worth trying if you have plateaued.
Are there withdrawal effects when switching GLP-1 medications?
No traditional withdrawal, but there may be a brief transition period where appetite control shifts. Since both medications target GLP-1 receptors, there is continuity of effect. Some patients notice different side effect profiles on the new medication.
Easy Switching with Trimi
Our clinicians guide medication transitions. Semaglutide from $99/mo, tirzepatide from $125/mo — switch seamlessly.
Get Started TodayMore on Recovery
Sources & References
- Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. NEJM 2021;384:989-1002.
- Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. NEJM 2022;387:205-216.
- Lincoff AM et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. NEJM 2023;389:2221-2232.
- FDA Prescribing Information for Wegovy (semaglutide) and Zepbound (tirzepatide).